Teva to Discontinue Phase 2 TOPAS-MSA Study After Futility Analysis
Teva will discontinue the Phase 2 TOPAS-MSA study of emrusolmin (TEV-‘286) following an interim futility analysis.
Related stories
More Than 10,000 US Flights Affected for Third Day
US air travel disruptions continued Sunday, with Transportation Secretary Sean Duffy predicting a return to normal by Monday as airlines worked to restore schedules.
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Thousands of US Flights Canceled, Delayed for Third Day in a Row
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Boeing-Lockheed Rocket Fails Mid-Flight, Destroying Amazon Satellites
M impact | EQUITY | Nov 15, 2026, 11:09 PM UTC
Samsung SDI Wins 16 GWh Battery Order From Jupiter Power
Samsung SDI's U.S. subsidiary signed an order for 16 GWh of batteries from Jupiter Power.
M impact | EQUITY | Nov 15, 2026, 11:05 PM UTC
Intel shareholders sue after 29% stock plunge
Intel shareholders sued the company following a 29% stock plunge, Reuters reported.
M impact | EQUITY | Nov 15, 2026, 11:03 PM UTC
Global market picture: S&P 500 -0.29%, Nasdaq 100 -0.38%; EUR/USD -0.28%, WTI +0.41%
Global market picture. US index futures: S and P futures is down 0.29 percent, Nasdaq futures is down 0.38 percent, Dow futures is down 0.14 percent and Russell futures is down 0.2
M impact | EQUITY | Nov 15, 2026, 11:01 PM UTC